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Introduction 
 
The clinical gold standard is bone auto-grafting, 
but autologous grafting can lead to donor site morbidity 
and limited donor site availability; allogeneic grafting 
can lead to infection. Polymer scaffolds or composites 
will be the best bone substitutes. Our early researches 
show that biodegradable hydrogels or microsphere 
comprehended hydroxyapatite(HAp), tricalcium 
phosphate(TCP) or other osteoconductive molecules 
will enhance bone defects repairing.1,2 The objective of 
our study was to investigate the in vivo performance of 
bone defects implanted with novel composite (thermo-
sensitive hydrogel mPEG-PLGA /HAp/TCP). 
 
Materials and Methods 
 
Lactide and glycolide were purchased from Purac. 
mPEG, stannous octoate, hydroxyapatite and tricalcium 
phosphate were purchased from Sigma. The details of 
synthesis and characterization of mPEG-PLGA could be 
found early report.3 
 Novel composite bone substitutes comprised 
different ratio of thermo-sensitive hydrogel mPEG-
PLGA/HAp/TCP: group I (hydrogel: HAp/TCP is 2:1, 
and HAp: TCP is 7:3), group II (hydrogel: HAp/TCP is 
2:1, and HAp: TCP is 5:5), group III (hydrogel: 
HAp/TCP is 2:1, and HAp: TCP is 3:7). 
 Ten New Zealand White rabbits were created a 
bone non-union defect by drill at right femur bones. 
Thermo-sensitive hydrogel/HAp/TCP composite was 
implanted into rabbit bone defect. Radiological studies 
were performed at timed intervals (2, 4, 8, and 12 
weeks). After 12 weeks follow-up time, histological 
studies of implanted PEG-PLGA was also assayed. 
 
Results & Discussion 
 
 mPEG-PLGA are mixed with ceramic powder 
(HAp/TCP). This type of composite can inject into bone 
defects in minimum invasive surgery applications with 
lower pain. 
 
 
 
 
Figure 1. mPEG-polyester/HAp/TCP injectable 
composite 
 
 The radiographic studies show that after 
12weeks post-operation, the group I defect is obscure 
under the x-ray, and seems that convalescence (Fig.2). 
However, the group III still has a obvious cavity. After 
μCT analyzed, we have the same results (Fig.3). 
 
 
 
 
 
 
Figure 2. radiographic studies.From left to right is 
autologous control, group I, group II and groupIII. 
 
 
 
 
 
 
Figure 3. μ CT studies.From left to right is 
autologous control, group I, group II and groupIII. 
 
Conclusion 
 
 The results validated the usage mPEG-PLGA 
hydrogel/HAp/TCP as bone substitute. Calcium ceramic 
with a ratio of HAP: TCP 7:3 had better 
osteoconductive bone formation than others but lesser 
than the auto-graft bone group. The next step of animal 
study will be verified the bone regeneration rate by 
BMP2 effecting. 
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